Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer

Objective:To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer.Methods:We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal lymph node dissection for metastatic testicular cancer between May 2018 and July 2021 at our institution.Data were collected on patient and tumour characteristics,intraoperative and postoperative parameters,and functional and oncological outcomes.Descriptive statistics are presented.Results:Nineteen patients were identified;18(94.7%)completed the procedure robotically and one was converted to open surgery;78.9%of patients had stage≥IIB and 12(63.2%)patients had undergone prior chemotherapy.The median operative time was 300(interquartile range[IQR]240-315)min.Median blood loss was 100(IQR 50-175)mL.Median length of stay was 2(range 1-11)days.All robotically completed patients commenced diet and passed flatus on Day 1 and were discharged by Day 3.The median lymph node yield was 40.5(IQR 38-51)nodes.All patients undergoing nerve-sparing procedures recovered antegrade ejaculatory function.One patient had a Clavien-Dindo III complication(chylous ascites requiring drainage).At a median follow-up of 22.3(IQR 16.3-24.9)months,one patient developed retroperitoneal recurrence,which was successfully treated with second-line chemotherapy;no other patients have had recurrences.Conclusion:Robotic retroperitoneal lymph node dissection is a safe and feasible alternative to open surgery in appropriately selected patients,offering low morbidity.Early oncological outcomes are promising.Larger cohorts and longer follow-ups are required to validate our institution's findings.

Management of Testicular Cancers in Brazzaville

Introduction: Testicular cancer accounts for 5% of urological tumors, predominantly affecting young men. The aim of our study was to report the diagnostic and evolutionary aspects of testicular cancer cases treated in our center. Patients and Methods: A retrospective study conducted over a 15-year period involving 12 patients treated for testicular cancer at the University Hospital of Brazzaville. Results: The median age was 31 years (range 11 to 49 years), with a median consultation delay of 10.6 months (range 3 to 27 months). Scrotal mass was the most common reason for consultation. Cancer was bilateral in two patients. Two patients were admitted with metastatic disease. Histopathological examination favored germ cell tumors in 7 cases, two cases of non-Hodgkin’s malignant lymphoma, and one case of epididymo-testicular adenocarcinoma. Adjuvant chemotherapy resulted in complete remission in patients with germ cell tumors. However, neoadjuvant chemotherapy was not effective in patients admitted with advanced-stage disease. Conclusion: Testicular cancer is a rare condition that is curable in the majority of cases, but its management is often complicated in our setting due to delayed diagnosis caused by taboos surrounding genital organ pathologies.

Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy

BACKGROUND Testicular germ cell tumor(TGCT)is the most curable solid tumor and most common cancer among men 18-39 years.While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGCT,it is associated with a high rate of thromboembolic events(TEE).AIM To summarize our single-center experience highlighting patients who were diagnosed with TGCT and received platinum-based chemotherapy,with special attention to those patients who suffered a TEE.METHODS A retrospective analysis of the medical records and imaging studies of 68 consecutive individuals who were diagnosed with TGCT and received platinumbased chemotherapy at our Institution in a metropolitan community between January 1,2014 and December 31,2019.RESULTS A total of 19(28%)patients experienced a TEE following orchiectomy which occurred during chemotherapy in 13(68%)of these patients.Patients with a higher pathologic stage(stage III)were significantly(P=0.023)more likely to experience a TEE compared to patients who had a lower stage.Additionally,patients who were treated with 3 cycles of bleomycine,etoposide,and cisplatin and 1 cycle of etoposide and cisplatin or 4 cycles of etoposide and cisplatin were significantly 5(P=0.02)times more likely to experience a TEE compared to patients who were treated with only 3 cycles of bleomycine,etoposide,and cisplatin.CONCLUSION Due to numerous factors that predispose to a TEE such as large retroperitoneal disease,higher clinical stage,greater number of chemotherapy cycle,central venous catheter,cigarette smoking,and possible cannabis use,high-risk ambulatory patients with TGCT treated with cisplatin-based chemotherapy may benefit from prophylactic anticoagulation.Randomized studies to evaluate the safety and efficacy of prophylactic anticoagulants are warranted in this young patient population generally devoid of medical co-morbidities.

Tumour lysis syndrome:A rare acute presentation of locally advanced testicular cancer--Case report and review of literature

Tumour lysis syndrome(TLS)is a potentially fatal complication of malignancy or its treatment.This uncommon syndrome comprises laboratory findings of hyperuricaemia,hypocalcaemia,hyperkalaemia and hyperphosphataemia.A literature search revealed a total of eight patients,with testicular cancer,who had TLS.All these patients had metastatic disease.We present a unique case of a 47-year-old gentleman we saw in clinic,who presented with a rapidly growing right groin mass and acute breathlessness,and discuss the diagnosis and management of TLS.TLS is extremely rare in testicular cancer but necessitates the awareness of urologists.TLS can occur spontaneously in testicular malignancy.Cell lysis in a rapidly proliferating germ cell tumour is a possible mechanism.The prompt identification and institution of management for TLS is crucial to improve clinical outcomes.

RELATIONSHIP BETWEEN THE INCIDENCE RATES OF TESTICULAR AND PROSTATIC CANCERS AND FOOD CONSUMPTIONS

Objective: To determine the relationships between the incidence rates of testicular and prostatic cancers and food consumptions in order to study the etiologic cause and the mechanism of the development of male genital organ cancer. Methods: The incidence rates of testicular and prostatic cancers in 42 countries (region) were correlated with the dietary practices in these countries. These data came from the cancer rate database (1988–1992) and the food supply database (1961–1990) provided by the Department of Environmental Health, Medical University of Yamanashi, Japan. Results: The incidence rates of testicular and prostatic cancers varied greatly from country to country but in China the rates of the both malignancies were lower than that of USA and Japan. This may be due to the difference in lifestyle, especially in dietary practices. Among the food items we examined, cheese was most closely correlated with the incidence of testicular cancer at ages 20–39, followed by animal fats and milk. The correlation coefficient (r) was the highest (r=0.804) when calculated for cheese consumed during the period of 1961–1965 (maternal or prepubertal consumption). Stepwise-multiple-regression analysis revealed that cheese (1961–1965) made a significant contribution to the incidence of testicular cancer. Multiple coefficient (r) is 0.920. As far as prostatic cancer was concerned, milk was most closely correlated (r=0.711) with its incidence, followed by meat and coffee. Stepwise-multiple-regression analysis identified milk, meat, butter and coffee as significant factors contributing to the incidence of prostatic cancer (R=0.993). The results of our study suggest a role of milk and dairy practices in the development of testicular and prostatic cancers.

Programmed cell death protein 4 expression in renal cell carcinoma, penile carcinoma and testicular germ cell cancer

AIM:To investigate the expression of programmed cell death 4(Pdcd4)tumor suppressor gene in tissue specimen of renal cell carcinoma(RCC),testicular germ cell cancer and penile cancer.METHODS:Pdcd4 expression was studied using immunohistochemistry in 188 cases of RCC and 28 controls(including 9 oncocytoma);in 74 cases of penile carcinoma(including 17 metastatic tissue samples)and26 controls;in 11 cases of seminoma,in 14 cases of non-seminoma and 5 controls.RESULTS:Control tissues exhibited strong core and cytoplasmatic Pdcd4 staining.In contrast,core and cy-toplasmatic Pdcd4 levels were significantly decreased in cancer tissues.CONCLUSION:Our data support a role for Pdcd4(down-)regulation in urologic tumors.Interestingly,Pdcd4 expression seem to be a potential diagnostic marker for renal or penile tumors.

1990-2019年中国睾丸癌疾病负担分析

目的分析1990-2019年中国睾丸癌疾病负担及变化趋势。方法基于2019年全球疾病负担数据库(GBD 2019),分析1990-2019年中国人群睾丸癌的发病、死亡、伤残调整寿命年(DALYs)、过早死亡损失寿命年(YLLs)、伤残损失寿命年(YLDs)及其变化趋势。通过计算年估计变化百分比(EAPC)评估年龄标准化率(ASR)的变化。按照年龄分组,分析睾丸癌疾病负担的年龄分布特点。结果2019年中国睾丸癌发病例数为17.17×103例,死亡例数为1.21×103例,年龄标准化发病率为2.39/10万,年龄标准化死亡率为0.16/10万。与1990年相比,发病例数、死亡例数、年龄标准化发病率均明显增加或增高,与全球变化趋势一致,而增幅均高于全球水平,但中国和全球年龄标准化死亡率均呈现下降趋势。1990-2019年,中国睾丸癌的DALYs、YLLs、YLDs均明显上升,分别增加了29.66%、9.83%、720.91%。0~15岁和30~35岁是睾丸癌高发的两个年龄段,30~35岁是我国睾丸癌疾病负担最重的年龄段。结论1990-2019年中国睾丸癌的疾病负担整体呈上升趋势。儿童和青壮年发病率较高、疾病负担较重,应作为睾丸癌的重点筛查及防治人群。

Fertility outcome of patients with testicular tumor： before and after treatment

Testicular cancer （TC） is the most curable type of cancer, with a survival rate of more than 95%. Oncologists are faced with the challenge that gonadotoxic cancer treatments can compromise future fertility, either temporarily or permanently. Our aim was to investigate the long-term effects of TC treatments on male fertility and on the offspring of patients who had received these treatments. Between January 1996 and December 2010, 125 eligible patients, ranging from 18 to 54 years （median age 36.3 _＋ 15.7）, with unilateral TC underwent surgery, chemotherapy or radiotherapy at our center. Some of these patients had their semen samples cryopreserved in the Shanghai Human Sperm Bank. The clinical data were evaluated, and questionnaire and telephone follow-up surveys were given to all patients. The data were analyzed to determine the patients＇ fertility status pre- and posttreatment. Of the 125 eligible patients, 93.6% （117/125） were accessible and were evaluated. Among 81 men who were married before diagnosis, 21 had conceived successfully before diagnosis and six reported azoospermia. Posttreatment conception was attempted by 73 men; of these, 16 conceived naturally and 19 conceived by artificial reproductive techniques, resulting in 37 healthy babies with no congenital malformations. Of the patients who had not conceived before treatment, 21.9% （21/96） banked their sperm and 23.8% of these patients （5/21） subsequently used the banked sperm. Retroperitoneal lymph node dissection, chemotherapy and radiotherapy were the most highly correlated with lack of conception to TC patients with the desire for biological conception. There is no birth defects or childhood malignancies. post-TC treatment. Sperm banking should be recommended evidence to suggest that TC treatments are associated with

人类示指与环指指长比与男性生殖系统癌症相关性的研究进展

人类示指与环指指长比(2D∶4D)是产前性激素(雌激素/雄激素)暴露水平及敏感性的宏观标记物之一,在性别间差异明显。产前性激素暴露对出生后个体的心理特征、运动能力及多种性激素相关疾病均有影响。本研究综述了2D∶4D与男性生殖系统癌症(前列腺癌和睾丸癌)相关性的研究进展,以期为此类疾病的早期筛查提供参考信息。

A rare diagnosis:testicular dysgenesis with carcinoma in situ detected in a patient with ultrasonic microlithiasis

A rare case is presented where a dysgenetic testis with microinvasive carcinoma in situ （CIS, also known as intratubular germ cell neoplasm of unclassified type [IGCNU] and testicular intraepithelial neoplasia [TIN]） with microinvasion to rete testis and the interstitial tissue was found in a 32-year-old man presenting with mild scrotal pain and ultrasonic testicular microlithiasis. Knowledge of the association of ultrasound and CIS is important to diagnose patients at the stage prior to development of an overt germ cell tumor. The patient had three of four disorders considered symptoms of the testicular dysgenesis syndrome （TDS）： a dysgenetic left testicle with CIS, a mild left-sided cryptorchidism （high positioned scrotal hypotrophic testis） and a slightly reduced semen quality. Therefore, it should be kept in mind that a patient with one TDS symptom may harbour the other, even CIS or testicular cancer. Accordingly, patients with one TDS symptom ought to be examined for the presence of the others, and if more that one is present, extra concern is warranted.

Clinical outcomes in patients with stage non-seminomatous germ cell cancer

This study assesses the long-term outcomes in Han Chinese patients with clinical stage I non-seminomatous germ cell testicular cancer （CSI NSGCT） treated with surveillance, retroperitoneal lymph node dissection （RPLND） and adjuvant chemotherapy. We retrospectively evaluated 89 patients with a mean age of 26.5 years. After orchiectomy, 37 patients were treated with surveillance, 34 underwent RPLND and 18 were managed with chemotherapy. The overall survival rate, the recurrence-free survival rate and the risk factors were evaluated. The median follow-up length was 92 months （range： 6-149 months）. Thirteen of the 89 patients （14.6%） had relapses, and one died by the evaluation date. The overall survival rate was 98.9%. The cumulative 4-year recurrence-free rates were 80.2%, 92.0% and 100% for the surveillance, RPLND and chemotherapy groups, respectively. The disease-free period tended to be briefer in patients with a history of cryptorchidism and those with stage Is. Therefore, surveillance, RPLND and adjuvant chemotherapy might be reliable strategies in compliant patients with CSI NSGCT. Surveillance should be recommended for patients with the lowest recurrence rate, especially those without lymphovascular invasion. This study might aid the establishment of a standard therapy for CSI NSGCT in China.

Assessment of Prognostic Factors of Racial Disparities in Testicular Germ Cell Tumor Survival in the United States(1992–2015)

Objective Testicular germ cell tumors(TGCT) are the most common cancer among men aged 15 to 39 years. Previous studies have considered factors related to TGCT survival rate and race/ethnicity, but histological type of the diagnosed cancer has not yet been thoroughly assessed.Methods The data came from 42,854 eligible patients from 1992 to 2015 in the Surveillance Epidemiology and End Results 18. Frequencies and column percent by seminoma and nonseminoma subtypes were determined for each covariates. We used Cox proportional hazard regression to assess the impact of multiple factors on post-diagnostic mortality of TGCT.Results Black males were diagnosed at a later stage, more commonly with local or distant metastases.The incidence of TGCT in black non-seminoma tumors increased most significantly. The difference in survival rates between different ethnic and histological subtypes, overall survival(OS) in patients with non-seminoma was significantly worse than in patients with seminoma. The most important quantitative predictor of death was the stage at the time of diagnosis, and older diagnostic age is also important factor affecting mortality.Conclusion Histological type of testicular germ cell tumor is an important factor in determining the prognosis of testicular cancer in males of different ethnic groups.

Occlusive Syndrome Revealing a Nonseminoma Germ Cell Tumor Metastatic Testicular

Testicular cancer is rare. The authors report the case of a young Senegalese 21, who has consulted for an occlusive syndrome evolving for 48 hours that prompted his hospitalization. Note that the patient has consulted several times to persistent inguinal scrotal pain, a big right purse with chronic analgesic requirements and anti-inflammatory. Occlusive before this table, abdominal pelvic CT was performed and highlighted the presence of lung metastases, a large pelvic lymph node casting bridging the inter vesico-rectal space and responsible for extrinsic compression of the small intestine, lymph node inter casting aorto-cellar and latero aortic liver and multiple secondary locations. Faced with this bundle of arguments, clinical and laboratory, metastatic testicular tumor was raised and measured tumor markers. A right orchiectomy by inguinal was made with histology: A non-seminomatous germ cell tumor stage III. After orchiectomy germinal markers were still high and there was the problem of persistent occlusive syndrome despite resuscitation. A chemotherapy regimen was initiated with 4 cycles of chemotherapy according to the protocol BEP (bleomycin, etoposide, cisplatin). A significant regression of occlusive syndrome with a decline in clinical symptoms was noted. The revaluation at 3 months, 6 months and 1 year were highlighted: A normal clinical examination associated with a persistent correction rate of germline markers and lack of active lesion at thoraco-abdominopelvic CT.

Survival analysis of children with stage Ⅱ testicular malignant germ cell tumors treated with surgery or surgery combined with adjuvant chemotherapy

For children with stage II testicular malignant germ cell tumors(MGCT), the survival is good with surgery and adjuvant chemotherapy. However, there is limited data on surgical results for cases in which there was no imaging or pathologic evidence of residual tumor, but in which serum tumor markers either increased or failed to normalize after an appropriate period of half-life time post-surgery. To determine the use of chemotherapy for children with stage II germ cell tumors, we analyzed the outcomes(relapse rate and overall survival) of patients who were treated at the Sun Yat-sen University Cancer Center between January 1990 and May 2013. Twenty-four pediatric patients with a median age of 20 months(range, 4 months to 17 years) were enrolled in this study. In 20 cases(83.3%), the tumors had yolk sac histology. For definitive treatment, 21 patients underwent surgery alone, and 3 patients received surgery and adjuvant chemotherapy. No relapse was observed in the 3 patients who received adjuvant chemotherapy, whereas relapse occurred in 16 of the 21 patients(76.2%) treated with surgery alone. There were a total of 2 deaths. Treatment was stopped for 1 patient, who died 3 months later due to the tumor. The other patient achieved complete response after salvage treatment, but developed lung and pelvic metastases 7 months later and died of the tumor after stopping treatment. For children treated with surgery alone and surgery combined with adjuvant chemotherapy, the 3-year event-free survival rates were 23.8% and 100%, respectively(P = 0.042), and the 3-year overall survival rates were 90.5% and 100%, respectively(P = 0.588). These results suggest that adjuvant chemotherapy can help to reduce the recurrence rate and increase the survival rate for patients with stage II germ cell tumors.

Testicular metastasis from gastric carcinoma:A case report

Gastric cancer(GC) is the most prevalent malignancy in the world,especially in China.GC has been postulated to spread via several different routes,including through hematogenous channels,lymphatic vessels,the seeding of peritoneal surfaces,direct extension through the gastric wall,and retrograde extension through the vas deferens or lymphatics.Testicular metastasis is rare.We show here a 53-year-old patient with GC who underwent a radical total gastrectomy approximately 22 mo ago after he presented with a sensation of heaviness and swelling of the right hemiscrotum.The diagnosis of metastatic adenocarcinoma was made after a rightside orchiectomy.We report the first case of testicular metastasis from gastric adenocarcinoma in China's Mainland and summarize the clinicopathologic features of the disease based on previously published papers.

基于TCGA和GTEx数据库分析GDF3在睾丸癌中的表达及意义

目的:通过生物信息学研究GDF3在睾丸癌中的表达及意义。方法:联合TCGA及GTEx数据库,通过差异分析和泛癌分析确定目标基因GDF3,通过UALCAN数据库分析睾丸癌中GDF3的临床相关性。基于R语言程序包“org.Hs.eg.db”,“clusterProfiler”,通过基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析研究GDF3在睾丸癌中潜在的功能。通过TISIDB数据库研究睾丸癌中GDF3与免疫趋化因子、免疫抑制剂的相关性。结果:GDF3在睾丸癌中显著高表达(P<0.001),且与临床分级(P<0.05)、肿瘤分型(P<0.001)密切相关。免疫相关性分析结果显示,GDF3与免疫趋化因子CCL26(rho=0.599,P<0.001)、CCL7(rho=0.525,P<0.001)、免疫抑制剂ADORA2A(rho=0.723,P<0.001)、PVRL2(rho=0.585,P<0.001)密切相关。结论:GDF3与睾丸癌的发生发展以及免疫微环境密切相关。

Nuclear receptors and pathogenesis of pancreatic cancer

Pancreatic ductal adenocarcinoma(PDAC)is a devastating disease with a median overall survival time of5 mo and the five years survival less than 5%,a rate essentially unchanged over the course of the years.A well defined progression model of accumulation of genetic alterations ranging from single point mutations to gross chromosomal abnormalities has been introduced to describe the origin of this disease.However,due to the its subtle nature and concurring events PDAC cure remains elusive.Nuclear receptors(NR)are members of a large superfamily of evolutionarily conserved ligand-regulated DNA-binding transcription factors functionally involved in important cellular functions ranging from regulation of metabolism,to growth and development.Given the nature of their ligands,NR are very tempting drug targets and their pharmacological modulation has been widely exploited for the treatment of metabolic and inflammatory diseases.There are now clear evidences that both classical ligand-activated and orphan NR are involved in the pathogenesis of PDAC from its very early stages;nonetheless many aspects of their role are not fully understood.The purpose of this review is to highlight the striking connections that link peroxisome proliferator activated receptors,retinoic acid receptors,retinoid X receptor,androgen receptor,estrogen receptors and the orphan NR Nur,chicken ovalbumin upstream promoter transcription factorⅡand the liver receptor homologue-1 receptor to PDAC development,connections that could lead to the identification of novel therapies for this disease.

睾丸混合性生殖细胞肿瘤11例诊治报告

目的 结合11例睾丸混合性生殖细胞肿瘤(MGCT)患者的临床资料探讨MGCT的诊治。方法 回顾性分析我科2017年3月-2022年8月收治的经术后病理证实为MGCT的11例患者的临床资料,总结其临床特点、治疗方式及治疗效果,并结合相关文献和指南进行讨论。结果 MGCT患者占我科同一时期收治睾丸肿瘤(TC)的18.3%(11/60),占生殖细胞肿瘤(GCT)的21.2%(11/52)。11例MGCT病例均为单侧病变,左侧7例,右侧4例,左右侧之比1.75∶1。发病年龄21~52岁,平均(29.8±8.7)岁。所有病例均接受单侧睾丸根治性切除术(RO),7例接受腹膜后淋巴结清扫术(RPLND)(其中1例为机器人辅助下RPLND),6例接受术后化疗,1例行术后放疗。随访2~66月,平均随访(31.9±20.9)月,随访期内所有病例未见复发转移。结论 MGCT是一种临床相对少见的恶性肿瘤,预后较精原细胞瘤(SGCT)差,规范诊治并兼顾各病理类型的特殊性能获得较长的生存。

睾丸癌铁死亡相关基因的生物信息学分析

目的 应用生物信息学方法分析睾丸癌与正常组织之间的铁死亡相关差异基因和枢纽基因,为睾丸癌的预后和治疗提供新的思路和生物标记物。方法 从TCGA和GTEx数据库下载睾丸癌组织(n=148)和正常组织(n=165)的转录组数据。采用R语言对样本进行主成分分析(PCA),获取睾丸癌基因表达矩阵并筛选差异表达基因,并与铁死亡数据库(FerrDb)中483个铁死亡背景基因取交集基因,获取睾丸癌铁死亡差异表达基因并进行基因本体(gene ontology,GO)分析和京都基因与基因组百科全书(Kyoto encyclopedia of genes and genomes,KEGG)分析;采用STRING数据库和Cytoscape软件构建蛋白质相互作用(PPI)网络,筛选前10个差异基因的关键枢纽基因并绘制基因热图;用GEPIA数据库分析枢纽基因在睾丸癌和正常组织的表达水平。从GEO数据库下载基因芯片GSE8607的转录组数据,用limma包进行差异分析,并提取前10个差异基因的表达谱数据,绘制睾丸癌相关的铁死亡差异基因热图进行验证。结果 差异表达分析共获得69个睾丸癌铁死亡相关差异基因,信号通路主要富集在铁死亡信号通路、NOD样受体信号通路、胞质DNA传感途径、JAKSTAT信号通路和Toll样受体信号通路;GO富集显示铁死亡相关的睾丸癌主要与氧化应激和对化学物质的应激反应相关。前10位铁死亡相关的睾丸癌枢纽基因在睾丸癌中表达量结果显示,TP53、IL-6、CD44、KRAS、HMOX1、PRDX1、SOX2和TXN在睾丸癌组织中升高,AR和GPX4表达量降低。GSE8607中提取的前10个关键基因的表达数据与TCGA联合GTEx数据分析结果一致。结论 睾丸癌铁死亡相关基因主要参与NOD样受体信号通路和JAK-STAT信号通路,TP53、IL-6、AR和GPX4可能是睾丸癌铁死亡相关治疗和预后的潜在生物标记物。

雷帕霉素增强RSL3对睾丸癌细胞I-10的增殖、侵袭与迁移的抑制作用

目的探究雷帕霉素增强RSL3对睾丸癌细胞I-10的增殖、侵袭与迁移能力的抑制作用。方法MTT法检测RSL3(TypeII)及合用雷帕霉素(RAPA)作用后I-10细胞的存活率。将RSL3(0~16μmol/L)分别以及联合16μmol/L雷帕霉素作用于睾丸癌细胞I-10,采用MTT法检测I-10细胞增殖抑制情况,利用集落克隆形成实验检测细胞增殖能力,采用划痕实验和Transwell小室检测I-10细胞的迁移与侵袭能力,采用流式细胞术检测I-10细胞的脂质活性氧水平,采用GSH和MDA检测试剂盒检测细胞中GSH和MDA含量,利用Westernblot检测细胞GPX4蛋白表达。结果随着RSL3浓度的提高,其对I-10细胞的毒性作用逐渐增强。在合用雷帕霉素后,对细胞的毒性进步一增强。与对照组相比,单用RSL3组I-10细胞集落形成数减少(P<0.05)、划痕愈合率降低(P<0.01)、侵袭和迁移细胞数减少(P<0.05)、脂质活性氧水平升高(P<0.0001)、GSH含量降低(P<0.01)、MDA含量升高(P<0.05)、GPX4蛋白表达水平降低(P<0.01);与单用RSL3组相比,雷帕霉素联用RSL3组集落形成数、侵袭和迁移细胞数进一步减少(P<0.05),划痕愈合率、GSH含量、GPX4蛋白表达水平进一步降低(P<0.01,P<0.05),脂质活性氧水平、MDA含量进一步升高(P<0.05,P<0.01)。结论雷帕霉素增强RSL3对睾丸癌细胞I-10的增殖、侵袭与迁移的抑制作用,其机制与其能够增强RSL3诱导的铁死亡有关。